192 results about "Mucoproteins" patented technology

The present invention relates to a composition comprising at least one mRNA encoding a combination of antigens capable of eliciting an (adaptive) immune response in a mammal, wherein the antigens are selected from the group consisting of 5T4 (Trophoblast glycoprotein, TPBG), Survivin (Baculoviral TAP repeat-containing protein 5; BIRC5), NY-ESO-1 (New York esophageal squamous cell carcinoma 1, CTAG1B), MAGE-C1 (Melanoma antigen family C1), MAGE-C2 (Melanoma antigen family C2), and MUC1 (Mucin 1). The invention furthermore relates to a vaccine comprising at least one mRNA encoding such a combination of antigens, and to the use of said composition (for the preparation of a vaccine) and / or of the vaccine for eliciting an (adaptive) immune response for the treatment of lung cancer, preferably of non-small cell lung cancer (NSCLC), and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the composition and / or the vaccine.

An extraction method and apparatus is provided for obtaining quick, safe and highly sensitive testing of any of a variety of body fluids including saliva, blood, urine or other fluids for drugs of abuse or other analytes. The apparatus includes a latchable extraction wand for obtaining body fluid samples from a subject which is adapted to maximize the portion of the body fluid sample that will go into a graduated bottle containing a buffer solution, and a testing device wherein the sample will be received and into which test strips can be inserted to determine levels of drugs of abuse or other analyte in the sample. In one of the methods of the invention, energy is imparted to the sample and buffer solution, such as by shaking, and this facilitates the reduction of sample viscosity, such as by promoting the breakdown of mucins when the sample is saliva.

Disclosed are compositions and methods for the inhibition of biofilm formation or reduction of existing or developing biofilms in a patient. These methods also inhibit the aggregation of bacteria that form biofilms in the airways. The methods include administering to a subject that has or is at risk of developing biofilms a compound or formulation that inhibits the formation or polymerization of actin microfilaments or depolymerizes actin microfilaments at or proximal to the site of biofilm formation. Such a compound can be administered in combination with a compound or formulation that inhibits the accumulation or activity of cells that are likely to undergo necrosis at or proximal to the site of biofilm formation (i.e., neutrophils). The methods and compositions can further include the use of anti-DNA and / or anti-mucin compounds, as well as other therapeutic compounds and compositions.

The present invention provides a variant of an immunoglobulin variable domain including (A) at least one CDR region and (B) framework regions flanking the CDR region, wherein the variant also contains (a) a CDR region having added or substituted therein at least on binding sequence and (b) the flanking framework regions, wherein the binding sequence is heterelogous to the CDR and is an antigenic sequence from a MUC-1 binding sequence.

The invention relates to the technical field of cosmetics for skin beautifying, and particularly relates to an application of a mussel adhesive protein in preparing cosmetics for skin beautifying. The application disclosed by the invention has the following main beneficial effects: 1, after a mussel adhesive protein-containing cosmetic is applied on the skin, a molecular layer is formed on the skin, and after most of moisture is evaporated, because the mussel adhesive protein has a strong pyknosis effect, the mussel adhesive protein can promote the uniform shrinkage of the skin, so that the skin forms a uniform and consistent shrinkage layer, and then the occurrence of large wrinkles is avoided, thereby achieving the effect of instant skin firming and wrinkle removal, and improving the firmness and wrinkle resilience of the skin; 2, the smoothness and glossiness of the skin are increased; 3, the action of stains is reduced; and 4, the mussel adhesive protein is non-toxic and harmless.

New synthetic Lipid-A analogs based on monosaccharide (1) and disaccharide (2) derivatives were designed and prepared in the present invention. Both structures (1) and (2) incorporate novel lipid structures (3) and (4) that are not found in nature. Also, novel disaccharide Lipid-A structures (2) that incorporate novel contingents of uniform lipids and where R1, R4 and R5 are the same substitution group of structure (III) were synthesized. Liposome formulations containing totally synthetic components such as synthetic Lipid-A and synthetic lipopeptide derived from tumor-associated MUC1 mucin are described along with their therapeutic utility. Comparative test results of immunostimulating properties and toxicity of Lipid-A analogs (1) and (2) are included.

The present invention provides novel α-O-linked glycoconjugates such as α-O-linked glycopeptides, as well convergent methods for synthesis thereof. The general preparative approach is exemplified by the synthesis of the mucin motif commonly found on epithelial tumor cell surfaces. The present invention further provides compositions and methods of treating cancer using the α-O-linked glycoconjugates.

Methods and related kits for differentiating pancreatic cancer from a benign pancreatic disease. The method includes assaying a patient biological sample for a total level of CA 19-9 antigen and for a glycan level in specific mucin(s), and comparing the total level of CA 19-9 antigen and the glycan level in the specific mucin(s) to statistically validated thresholds, wherein a different level of total CA 19-9 antigen in the patient biological sample as compared to a statistically validated threshold and a different level of glycan level in the specific mucin(s) as compared to statistically validated thresholds indicate pancreatic cancer in the patient rather than a benign pancreatic disease.

The invention discloses a method for preparing a high-purity taste-removing purple sweet potato pigment, and belongs to the field of food additives and agricultural product deep processing. The method for preparing the high-purity taste-removing purple sweet potato pigment comprises the steps that 1, pretreatment is conducted on purple sweet potato raw materials; 2, the purple sweet potato pigment is extracted from low-frequency microwave auxiliary acidified aqueous solution; 3, preliminary purification is conducted on macroporous resins; 4, high-speed counter-current chromatography separation and purification are conducted, and the taste-removing purple sweet potato pigment with concentration more than 95% is obtained. According to the method for preparing the high-purity taste-removing purple sweet potato pigment, the microwave auxiliary acidified aqueous solution is used for extraction, flocculants are added to flocculate mucoproteins, then macroporous resin static adsorption and dynamic elution are conducted, and the taste-removing and enrichment purification process is preliminarily accomplished, and the high-purity taste-removing purple sweet potato pigment is finally prepared through the high speed counter-current chromatography method in a separation mode. According to the method for preparing the high-purity taste-removing purple sweet potato pigment, technological processes are advanced, separation efficiency is high, recovery rate is high, product purity is more than 95%, preparation amount is large, an obtained product is free of peculiar smell, has few impurities and is good in solubility, and method for preparing the high-purity taste-removing purple sweet potato pigment is easy to popularize and use.

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to an epitope located within the second to fourth cysteine-rich domains of MUC5ac (amino acid residues 1575-2052) and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.

The invention relates to a hemostasis composite material based on chitosan and marine mussel mucin and a specific preparation method of the hemostasis composite material. The hemostasis composite material comprises a chitosan type hydrogel carrier and the marine mussel mucin guided into the chitosan type hydrogel carrier. The hemostasis composite material is soft in texture, high in application performance, applicable to hemostasis of body-surface wounds and bleeding of parts such as internal tissue and organs, and excellent in hemostasis effect.

The present invention pertains to anti-mucin antibodies having improved antigen binding and / or recognition properties as well as a method for improving the antigen binding and / or recognition of an anti-mucin antibody. In particular, the present invention is directed to anti-MUC1 antibodies which are useful in the treatment of cancer.

Provided are expression vectors for generating an immune response to a mucin. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal, a mucin antigen and CD40 ligand. Also provided are methods of generating an immune response against cells expressing a mucin by administering an effective amount of the vector. Further provided are methods of generating an immune response against cancer cells expressing a mucin in an individual by administering an effective amount of the vector. Still further provided are methods of overcoming anergy to a mucin self antigen by administering an effective amount of the vector.

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to pancreatic cancer mucins such as MUC1 or MUC5ac and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. Alternatively, immunoassay with PAM4 and anti-CA19.9 antibodies may be utilized to improve sensitivity for pancreatic cancer.

The invention provides a process for extracting yam mucoproteins from yams and belongs to the field of extracting functional biological macromolecular substances from natural materials to produce functional healthcare food. The extracting process comprises the main steps of (1) material selection; (2) leaching gelatinization; (3) enzymolysis; (4) standing; (5) adjustment of PH value; (6) flocculation; (7) precipitation; and (8) drying. The yield of the yam mucoprotein products prepared by the process is 4 to 5 percent, and the content of yam mucoprotein is 60 to 67 percent. According to the process provided by the invention, the organic solvent extraction in the prior art is replaced by the flocculation and natural precipitation, so the product cost is greatly saved, the environmental pollution is lowered, and the process has great significance for actual production.

The present invention relates to the use of type 2 cytokines and mucins for increasing the amount or activity of bacterial species of the Clostridia class in the gastrointestinal tract, for treating dysbiosis in the gastrointestinal tract, for treating gastrointestinal and inflammatory disorders, and for promoting wound healing in the gastrointestinal tract.

The invention discloses a preparation method of saliva extracellular vesicles and application of the saliva extracellular vesicles to molecular diagnosis.The preparation method includes the steps of removing high-abundance proteins from saliva samples, filtering out mucoproteins, separating and extracting the extracellular vesicles, characterizing the obtained extracellular vesicles, extracting extracellular vesicle proteins, identifying the extracellular vesicle proteins and applying the extracellular vesicle proteins to lung cancer biomarker discovery.Currently, a normalized saliva extracellular vesicle preparation technology is absent, and high-abundance protein interference and background impurity interference, existing in existing preparation technologies, result in shortcomings of low extracellular vesicle recovery rate, fewer identified proteins and the like, so that true extracellular vesicle proteomics information can be reflected difficultly.The preparation method of the saliva extracellular vesicles and application of the saliva extracellular vesicles to molecular diagnosis have the advantages that saliva of healthy adult volunteers and lung cancer patients is taken as the samples, and an affinity chromatography and membrane separation combined technology is adopted, so that after the high-abundance proteins and the mucoproteins of the saliva are removed, the extracellular vesicles in the saliva are extracted centrifugally, proteomes of the extracellular vesicles are analyzed and more extracellular vesicle proteins are identified.

Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vectors comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing an antigen and CD40 ligand. Administration of a fusion protein containing the antigen and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. The invention methods may be used to generate an immune response against cancer expressing a tumor antigen such as a mucin or human papilloma viral tumor antigen and to generate an immune response against an infectious agent. Also provided is a method for simultaneously producing the expression vector and the fusion protein.

Compositions for use in treatment of a variety of tissue diseases include stem cells and stem cell released molecules (SRM's) suspended in an aqueous solution with a cellulosic material or other thickening agent. The stem cells and SRM's can be derived from one or more distinct cell lines. The SRM's can further include one or more mucins, cytokines, or growth factors. Exemplary formulations include stem cells and SRMs derived from epithelial stem cells, corneal limbal stem cells, and fibroblasts. Other compositions and methods for formulation thereof are described.

The invention discloses a method for culturing an artificial cartilage with different curved surfaces or a bone cartilage under the action of rolling load and sliding load. The method comprises an incubator which contains O2 and CO2 and can perform temperature adjustment and cell culture, perfusion and other conditions which are used for keeping culture solution fresh, and active factors which are added to the culture solution. The method is characterized in that culture blanks with different curved surfaces are fixed on the bottom plate of a culture room; during the culturing process, a culture is subjected to the effect of the rolling load and the sliding load simultaneously, and the culture is cultured into cartilage tissues or bone cartilage complex tissues. The method has the advantages that under the effect of the rolling load and the sliding load, the loading way of the method is closer to the mechanical environment of the growth and the development of the cartilage tissues; and under the loading condition, the method is favor of the growth and the development of cells and tissues. An experiment shows that mucopolysaccharide secreted by cartilage cells under the effect of the rolling load and the sliding load is higher than the mucopolysaccharide secreted by the cartilage cells only under the effect of the rolling load. After being cultured, the cultures with different shapes can be taken as implants, and the method of the invention is applied in repairing the defect of the cartilage in different parts.

The invention discloses a novel sputasol for isolated culture of Legionnella, which can be used for sputamentum digestion in isolated culture of Legionnella and can be also used as a digestive juice for conventional bacterial culture of clinical sputamentum. The sputasol comprises the following components: 2.0g of dithiothreitol (DTT), 0.894g of ethylene diamine tetraacetic acid (EDTA), 0.4g of potassium chloride, 3.6g of dipotassium hydrogen phosphate, 0.4g of potassium dihydrogen phosphate and 100g of water. By using the DTT, the sputasol breaks disulfide bonds in mucoproteins, thereby degrading the mucoproteins and digesting the sputamentum. By adding the EDTA into the sputasol, the EDTA can react with alkali metal, rare earth elements, transition metal and the like to form stable water-soluble complexes, thereby avoiding the poison of heavy metallic salts on the Legionnella. A buffer system comprises KCl, K2HPO4, KH2PO4 and other potassium salts and avoids the inhibiting effect of Na<+> ions on the Legionnella, thereby improving the positive rate in isolated culture of the Legionnella.

The invention relates to a chimeric antigen receptor and an expression gene thereof, a double-antigen regulated type T cell modified by the chimeric antigen receptor, and application thereof. The expression gene of the chimeric antigen receptor comprises a first fusion protein expression gene and a second fusion protein expression gene, wherein the first fusion protein expression gene comprises a mucoprotein-1 antibody expression gene, a notch receptor expression gene and a Gal4-VP64 transcription activating protein expression gene which are sequentially connected; the second fusion protein expression gene comprises a Gal4-UAS promoter expression gene and an anti-mesothelin expression gene which are sequentially connected. By adopting the innovative design, the chimeric antigen receptor has the advantages that the chimeric antigen receptor can be successfully imported into the T cell to form the T cell modified by the chimeric antigen receptor; the immune reaction cannot be produced until the mucoprotein-1 and the anti-mesothelin signals simultaneously exist, so as to reach the controllable immune reaction of the chimeric antigen receptor, fewer side effects in treatment, and high specificity.

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to an epitope located within the second to fourth cysteine-rich domains of MUC5ac (amino acid residues 1575-2052) and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay.

This invention provides methods, processes, compounds and compositions for modulating the gene expression and modulating the secretion, expression, or synthesis of adhesion proteins or their receptors to cure disease, wherein the modulating comprises positive and negative regulating; wherein comprises inhibiting cancer growth, wherein the adhesion proteins or receptors comprise fibronectin, integrins family, Myosin, vitronectin, collagen, laminin, Glycosylation cell surface proteins, polyglycans, cadherin, heparin, tenascin, CD 54, CAM, elastin and FAK; wherein the methods, processes, compounds and compositions are also for anti-angiogenesis; wherein the cancers comprise breast cancer, leukocyte cancer, liver cancer, ovarian cancer, bladder cancer, prostate cancer, skin cancer, bone cancer, brain cancer, leukemia cancer, lung cancer, colon cancer, CNS cancer, melanoma cancer, renal cancer or cervix cancer.

The invention relates to the technical field of mucin 1 detection, in particular to a fluorescent biological probe for mucin 1 detection, a sensor, application and a detection method. In the present invention, the aptamer probe is used for an Exo I assisted target circulation (EATR) reaction. The hairpin probe comprises a hairpin probe H1 and a hairpin probe H2 which are used for GO-assisted hybridization chain reaction (HCR); the aptamer probe and the hairpin probe are combined to be used for mucin 1 detection, so organic combination of Exo I-assisted target circulation reaction and GO-assisted hybridization chain reaction can be realized; therefore, cascade amplification of fluorescence signals is realized, the detection sensitivity of mucoprotein 1 is remarkably improved, the detectionlimit is reduced, quantitative detection of low-concentration mucin 1 can be realized, and theprobe has high specificity and can be used for specifically identifying and detecting mucin 1.

The invention discloses a method for detecting miRNA (micro ribonucleic acid) in stomach juice, which comprises stomach juice extraction and neutralization, RNA release, chloroform extraction, isopropanol precipitation, ethanol washing, RNA reverse transcription, PCR (Polymerase Chain Reaction) detection and other steps. In the detection method, a sodium hydroxide solution is used to liquefy viscous components in the stomach juice, so that mucoproteins and polysaccharides are suspended in the solution, and the stomach juice is neutralized; trypsinase is added to carry out digestion, so that the mucoproteins and other proteins can be hydrolyzed, and cell components in the stomach juice are loosened at the same time, thereby facilitating centrifugal separation; and a Trizol solution is added to carry out repeated blow and beat, so that the RNA is completely released and separated from the polysaccharides, the mucoproteins and other impurities, thereby solving the problem that the RNA extraction can be disturbed by the acidity of the stomach juice as well as polysaccharides, mucoproteins and the like in the stomach juice. Thus, the invention can eliminate the disturbance caused by polysaccharides, proteins and other impurities in the stomach juice, complete the efficient extraction of miRNA in the stomach juice and carry out fluorescent quantitative PCR detection on the extracted miRNA.

A pharmaceutical composition for intraperitoneal delivery of an anti-neoplastic agent is provided for treating cancers associated with aberrant mucin expression, preferably ovarian cancer and pancreatic, prostate, metastatic breast, bladder and lung cancers. The composition comprises nanomicelles loaded with the anti-neoplastic agent, and antibodies such as anti-MUC16, anti-MUC1 or anti-MUC4 are conjugated to these nanomicelles. The antibody-bound nanomicelles are optionally embedded in a biodegradable pH- and thermo-responsive hydrogel capable of sol-gel transition at body temperature. The pharmaceutical composition is implantable in the peritoneum, where it transforms into a semi-solid gel at the body's core temperature. In response to pH, the hydrogel swells and releases the antibody-bound nanomicelles. The nanomicelles specifically target mucin antigens on cancer cells. The anti-mucin antibodies can be internalized by the tumour cells, enabling the drug-loaded nanomicelles to gain entry and deliver the chemotherapeutic drugs inside the tumour cell.

Described herein are compositions and methods of use of anti-pancreatic cancer antibodies or fragments thereof, such as murine, chimeric, humanized or human PAM4 antibodies. The antibodies show novel and useful diagnostic characteristics, such as binding with high specificity to pancreatic and other cancers, but not to normal or benign pancreatic tissues and binding to a high percentage of early stage pancreatic cancers. Preferably, the antibodies bind to pancreatic cancer mucins such as MUC1 or MUC5ac and are of use for the detection and diagnosis of early stage pancreatic cancer. In more preferred embodiments, the anti-pancreatic cancer antibodies can be used for immunoassay of serum samples, wherein the immunoassay detects a marker for early stage pancreatic cancer in serum. Most preferably, the serum is extracted with an organic phase, such as butanol, before immunoassay. Alternatively, immunoassay with PAM4 and anti-CA19.9 antibodies may be utilized to improve sensitivity for pancreatic cancer.

Provided are antibodies that specifically bind to T-cell immunoglobulin domain and mucin domain 3 (Tim-3). The anti-Tim-3 antibodies can be used to treat, prevent or diagnose immune, cancerous, infectious diseases or other pathological disorders that may be modulated by Tim-3-mediated functions.